151 related articles for article (PubMed ID: 15287688)
1. [Resumption-inhibition in presynaptic action: the medicinal].
Schubert-Zsilavecz M; Stark H
Pharm Unserer Zeit; 2004; 33(4):282-7. PubMed ID: 15287688
[No Abstract] [Full Text] [Related]
2. Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake.
Boot JR; Brace G; Delatour CL; Dezutter N; Fairhurst J; Findlay J; Gallagher PT; Hoes I; Mahadevan S; Mitchell SN; Rathmell RE; Richards SJ; Simmonds RG; Wallace L; Whatton MA
Bioorg Med Chem Lett; 2004 Nov; 14(21):5395-9. PubMed ID: 15454233
[TBL] [Abstract][Full Text] [Related]
3. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
[TBL] [Abstract][Full Text] [Related]
4. Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
Orjales A; Mosquera R; Toledo A; Pumar MC; García N; Cortizo L; Labeaga L; Innerárity A
J Med Chem; 2003 Dec; 46(25):5512-32. PubMed ID: 14640559
[TBL] [Abstract][Full Text] [Related]
5. Thiophene derivatives: a new series of potent norepinephrine and serotonin reuptake inhibitors.
Zhang A; Zhou G; Rong SB; Johnson KM; Zhang M; Kozikowski AP
Bioorg Med Chem Lett; 2002 Apr; 12(7):993-5. PubMed ID: 11909701
[TBL] [Abstract][Full Text] [Related]
6. Regulatory effects of reboxetine treatment alone, or following paroxetine treatment, on brain noradrenergic and serotonergic systems.
Gould GG; Pardon MC; Morilak DA; Frazer A
Neuropsychopharmacology; 2003 Sep; 28(9):1633-41. PubMed ID: 12825093
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters.
Ravna AW; Sylte I; Dahl SG
J Pharmacol Exp Ther; 2003 Oct; 307(1):34-41. PubMed ID: 12944499
[TBL] [Abstract][Full Text] [Related]
8. Lack of cocaine effect on dopamine clearance in the core and shell of the nucleus accumbens of dopamine transporter knock-out mice.
Budygin EA; John CE; Mateo Y; Jones SR
J Neurosci; 2002 May; 22(10):RC222. PubMed ID: 12006604
[TBL] [Abstract][Full Text] [Related]
9. Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transporter inhibitors.
Zhang A; Zhou G; Hoepping A; Mukhopadhyaya J; Johnson KM; Zhang M; Kozikowski AP
J Med Chem; 2002 Apr; 45(9):1930-41. PubMed ID: 11960503
[TBL] [Abstract][Full Text] [Related]
10. Neurotransmission of cognition, part 2. Selective NRIs are smart drugs: exploiting regionally selective actions on both dopamine and norepinephrine to enhance cognition.
Stahl SM
J Clin Psychiatry; 2003 Feb; 64(2):110-1. PubMed ID: 12633117
[TBL] [Abstract][Full Text] [Related]
11. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Eur J Pharmacol; 2003 Feb; 461(2-3):99-104. PubMed ID: 12586204
[TBL] [Abstract][Full Text] [Related]
12. Exaggerated effect of fluvoxamine in heterozygote serotonin transporter knockout mice.
Montañez S; Owens WA; Gould GG; Murphy DL; Daws LC
J Neurochem; 2003 Jul; 86(1):210-9. PubMed ID: 12807440
[TBL] [Abstract][Full Text] [Related]
13. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
[TBL] [Abstract][Full Text] [Related]
14. Transport mechanisms governing serotonin clearance in vivo revealed by high-speed chronoamperometry.
Daws LC; Montañez S; Owens WA; Gould GG; Frazer A; Toney GM; Gerhardt GA
J Neurosci Methods; 2005 Apr; 143(1):49-62. PubMed ID: 15763136
[TBL] [Abstract][Full Text] [Related]
15. Studies towards the next generation of antidepressants. Part 1: Indolylcyclohexylamines as potent serotonin reuptake inhibitors.
Meagher KL; Mewshaw RE; Evrard DA; Zhou P; Smith DL; Scerni R; Spangler T; Abulhawa S; Shi X; Schechter LE; Andree TH
Bioorg Med Chem Lett; 2001 Jul; 11(14):1885-8. PubMed ID: 11459653
[TBL] [Abstract][Full Text] [Related]
16. Beyond monoamine-based therapies: clues to new approaches.
Skolnick P
J Clin Psychiatry; 2002; 63 Suppl 2():19-23. PubMed ID: 15453010
[TBL] [Abstract][Full Text] [Related]
17. Long-term modulation of presynaptic 5-HT-output: experimentally induced changes in cortical 5-HT-transporter density, tryptophan hydroxylase content and 5-HT innervation density.
Huether G; Zhou D; Rüther E
J Neural Transm (Vienna); 1997; 104(10):993-1004. PubMed ID: 9503252
[TBL] [Abstract][Full Text] [Related]
18. Cocaine-like discriminative stimulus effects of heroin: modulation by selective monoamine transport inhibitors.
Rowlett JK; Platt DM; Spealman RD
J Pharmacol Exp Ther; 2004 Jul; 310(1):342-8. PubMed ID: 14985417
[TBL] [Abstract][Full Text] [Related]
19. Biaryl analogues of conformationally constrained tricyclic tropanes as potent and selective norepinephrine reuptake inhibitors: synthesis and evaluation of their uptake inhibition at monoamine transporter sites.
Zhou J; Zhang A; Kläss T; Johnson KM; Wang CZ; Ye YP; Kozikowski AP
J Med Chem; 2003 May; 46(10):1997-2007. PubMed ID: 12723962
[TBL] [Abstract][Full Text] [Related]
20. Neurotransmission of cognition, part 3. Mechanism of action of selective NRIs: both dopamine and norepinephrine increase in prefrontal cortex.
Stahl SM
J Clin Psychiatry; 2003 Mar; 64(3):230-1. PubMed ID: 12716261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
